- FDA approval marks a significant breakthrough for the approximately 3 million adults in the U.S. with heart failure with preserved ejection fraction, which has been classified as "the single largest ...

Key secondary outcomes include cardiovascular death or hospitalization for heart failure, all-cause hospitalization and all-cause mortality. EMPA-KIDNEY includes 6,609 adults randomized from eight ...

The FDA approved Eli Lilly’s Jardiance to reduce the risk of cardiovascular death and hospitalization for heart failure in adults, the agency said Feb. 24. The drug was originally approved by the FDA ...

The study will assess whether in-hospital administration of Jardiance 10 mg daily improves heart failure outcomes when initiated in people hospitalized for any type of acute heart failure event once ...

The double-blind EMPEROR-Reduced trial enrolled 3730 adults with HFrEF, with and without diabetes. Boehringer Ingelheim and Lilly announced positive topline results from a phase 3 trial evaluating the ...

Approval adds to the treatment options for the more than 35 million adults in the U.S. affected by chronic kidney disease (CKD) Jardiance ® (empagliflozin) 10 mg tablets significantly reduced the risk ...

The Food and Drug Administration approved Eli Lilly’s Jardiance (empagliflozin) for treating adults with chronic kidney disease (CKD) on Friday morning. The agency approved 10 mg tablets of Jardiance ...

With a European approval for chronic kidney disease nod in hand, Boeringer Ingelheim and Eli Lilly's Jardiance is looking to catch up to AstraZeneca's Farxiga in this use and continue growing its ...

Eli Lilly LLY announced that the FDA has expanded the label of its diabetes drug, Jardiance (empagliflozin), to chronic kidney disease (“CKD”). Jardiance is now approved in the United States to reduce ...

Please provide your email address to receive an email when new articles are posted on . Health Canada has approved the use of Jardiance for the treatment of adults with chronic kidney disease. More ...

RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 22, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) 10 mg tablets to reduce the risk of sustained ...